| Literature DB >> 34731369 |
Ramy Alam1, Yara Mrad2, Hussein Hammoud1, Zahraa Saker1, Youssef Fares1,3, Elias Estephan1, Hisham F Bahmad4, Hayat Harati5, Sanaa Nabha6.
Abstract
Alzheimer's disease (AD), acknowledged as the most common progressive neurodegenerative disorder, is the leading cause of dementia in the elderly. The characteristic pathologic hallmarks of AD-including the deposition of extracellular senile plaques (SP) formation, intracellular neurofibrillary tangles, and synaptic loss, along with prominent vascular dysfunction and cognitive impairment-have been observed in patients. Fibroblast growth factors (FGFs), originally characterized as angiogenic factors, are a large family of signaling molecules that are implicated in a wide range of biological functions in brain development, maintenance and repair, as well as in the pathogenesis of brain-related disorders including AD. Many studies have focused on the implication of FGFs in AD pathophysiology. In this review, we will provide a summary of recent findings regarding the role of FGFs and their receptors in the pathogenesis of AD, and discuss the possible opportunities for targeting these molecules as novel treatment strategies in AD.Entities:
Keywords: Alzheimer’s disease; Fibroblast growth factor; Fibroblast growth factor receptor; Neuroprotection; Therapeutic target
Mesh:
Substances:
Year: 2021 PMID: 34731369 DOI: 10.1007/s11033-021-06890-0
Source DB: PubMed Journal: Mol Biol Rep ISSN: 0301-4851 Impact factor: 2.316